PGR抗体;PGR Antibody—艾普蒂

+ +

•  

   

     Black line: Control Antigen (100 ng);Purple line: Antigen (10ng); Blue line: Antigen (50 ng); Red line: Antigen (100 ng)    

  
  

•  

   

     Flow cytometric analysis of Hela cells using PGR mouse mAb (green) and negative control (red).    

  
  

•  

   

     Immunohistochemical analysis of paraffin-embedded human breast cancer tissues using PGR mouse mAb with DAB staining.    

  
  

•  

   

     Immunohistochemical analysis of paraffin-embedded human rectal cancer tissues using PGR mouse mAb with DAB staining.    

  
  

**Background of PGR Antibodies**

Progesterone receptor (PGR) antibodies are essential tools in studying and diagnosing hormone-responsive tissues and diseases, particularly in breast and reproductive cancers. PGR, a nuclear receptor encoded by the *PGR* gene, exists as two main isoforms, PRA and PRB, generated via alternative promoter usage. These receptors mediate progesterone’s effects, regulating gene expression involved in menstrual cycle regulation, pregnancy maintenance, and mammary gland development.

In clinical pathology, PGR antibodies are widely used in immunohistochemistry (IHC) to assess receptor expression in tumor tissues. In breast cancer, PGR status—alongside estrogen receptor (ER)—is a critical biomarker for molecular subtyping and treatment guidance. Tumors expressing PGR are typically hormone-sensitive, indicating potential responsiveness to endocrine therapies like tamoxifen or aromatase inhibitors. PGR positivity is also associated with favorable prognosis and lower aggressiveness.

Research highlights PGR's dual role: PRB promotes cell proliferation and differentiation, while PRA may inhibit these effects. Dysregulated PGR expression is linked to endocrine resistance, tumor progression, and gynecological disorders like endometriosis. Beyond oncology, PGR antibodies aid in studying normal physiology, such as endometrial remodeling and ovarian function.

Despite advancements, challenges remain, including standardization of IHC scoring and understanding isoform-specific roles. Ongoing studies aim to refine PGR’s predictive value and explore its interplay with other signaling pathways, enhancing personalized therapeutic strategies.